Vantis. (3/12/25). "Press Release: Munich-based HealthTech Startup Vantis Secures 10 Million Euros in Series A Financing Round Led by Angelini Ventures". Munich.

	Organisation	Vantis GmbH
	Organisation 2	Angelini Ventures S.p.A.
	Product	digital health (healthcare informatics)
	Product 2	venture capital
	Index term	Vantis–SEVERAL: investment, 202503 financing round Series A €10m led by Angelini Ventures
	Person	Jansen, Till (Vantis 202503 CEO + Co-Founder)
	Person 2	Bottler, Nils (Angelini 202503 Principal for Digital Health at Angelini Ventures)

Munich-based HealthTech company Vantis - a provider specializing in chronically ill patients and covering the entire spectrum of GP care in addition to digital therapies - has raised millions in a further financing round. The investors include Angelini Ventures, Bayern Kapital and Twip Impact Ventures. In addition, the existing investors firstminute and b2venture also participated again in this round.

Germany is facing a massive challenge in terms of GP care: While the number of chronically ill patients continues to grow, the shortage of doctors is getting worse. Today, around 30 percent of general practitioners are already over 55 years old. According to calculations by the Robert Bosch Stiftung, there could be a shortage of over 10,000 GPs in Germany by 2035. Rural regions in particular are at risk of a significant shortage. [1]

Vantis addresses this problem with a combination of technology-based efficiency enhancement and optimized practice organization. Data-based treatment methods and the digitalization of practice processes can significantly increase the number of treatable patients per doctor. At the same time, the integration of digital therapy approaches enables more intensive, data-supported care - especially for the chronically ill.

The fresh capital will be used to further expand the data-driven, proactive management of chronically ill patients. The aim is to create modern, digitally networked care structures that relieve the burden on medical professionals and sustainably improve treatment outcomes for patients. To achieve this, Vantis relies on innovative solutions such as telemedicine, data-driven remote monitoring and digital therapies, as well as processes supported by artificial intelligence (AI).

In order to achieve this and other ambitious goals, Vantis is planning to significantly expand the team: Significant investments will be made in the Munich headquarters in particular, including in the areas of tech, operations and management. In addition, the scaling of the outpatient care network will be a high priority for Vantis.

Till Jansen, co-founder and CEO of Vantis, emphasized: "Considerable investment is needed for the digital transformation of the healthcare system so that everyone benefits in the end - doctors, patients and payers. As a digital healthcare company with our own practices, we have the unique opportunity to tailor our technology to the current and future challenges in GP care and to continuously optimize it. Our aim is to achieve better treatment outcomes for patients and make doctors' day-to-day work easier so that they can focus more on medical care."

"Vantis is redefining GP care by combining digital innovation with practical clinical expertise. This approach not only simplifies processes in practices, but also enables doctors to provide more personalized and data-based care - especially for people with chronic conditions. This is in line with our aim of supporting companies that drive concrete, technology-based improvements in the healthcare sector, explains Nils Bottler, Principal for Digital Health at Angelini Ventures.

Monika Steger, Managing Director of Bayern Kapital, adds: "We invest in young companies that are prepared to challenge the status quo and bring innovations to the market. With the combination of its own GP practices and complementary innovative digital health applications, Vantis is pursuing the goal of sustainably improving GP care for doctors and patients. This forward-looking strategy makes Vantis a promising investment for us. The company offers a solution that is in tune with the times and addresses the growing requirements in the healthcare market. In addition, Vantis impresses with a diversified, solid business model and attractive growth prospects."

About Vantis

Vantis is a Munich-based company and a pioneer in digital healthcare. The company addresses one of the biggest challenges in the German healthcare system: more patients, fewer doctors.

Through the targeted use of digital technologies and innovative treatment methods, Vantis combines the best of medicine, technology and efficient practice organization. To this end, Vantis invests into its own network of general medical practices in order to guarantee nationwide, future-proof medical care.

https://www.vantis-health.com/de/

About Angelini Ventures

Angelini Ventures, the venture capital arm of Angelini Industries, is a specialized Series A and Series B investment firm driving disruptive innovation and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million in a global portfolio in Europe and North America, drawing on an international team, strategic advisors and partners to help entrepreneurs develop their innovations and grow them into transformative, market-leading companies.

To date, Angelini Ventures has invested around 100 million euros in 18 start-ups covering a variety of therapeutic areas and modalities. Angelini Ventures' biotech portfolio includes Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics, Cadence Neuroscience and Freya Biosciences, while the digital health portfolio includes Vantis Health, Nobi, Noctrix, Avation and Serenis.

www.angeliniventures.com

About Bayern Kapital

Bayern Kapital is the venture capital company of the Free State of Bavaria and, with 700 million euros under management, investments of up to 25 million euros per company, over 110 active portfolio companies and 30 years of experience in the VC business, is one of the most active, financially strongest and most experienced investors in the DACH region. Bayern Kapital invests in a consortium with private investors in Bavarian high-tech and deep-tech start-ups and scale-ups with innovative business models from all sectors, from the seed and scale-up phase through to exit.

Since it was founded in 1995, Bayern Kapital has invested over 500 million euros of its own equity capital in more than 320 start-ups and scale-ups from sectors such as life sciences, software & IT, materials & new materials, nanotechnology and environmental technology. This has created over 10,000 permanent jobs in sustainable companies in Bavaria.

Examples of numerous pioneering success stories that Bayern Kapital has supported from an early stage include Casavi, Catalym, commercetools, egym, EOS, Fazua, Immunic, Isar Aerospace, IQM, Parcellab, Proglove, Qbilon, Riskmethods, SimScale, Sirion, tado, Tubulis and many more.

www.bayernkapital.de

About Twip Impact Ventures

Twip Impact Ventures is a Munich-based European investor focused on digital, sustainable startups from seed to Series A stage. Twip offers capital investments combined with IT services to minimize technical risks and accelerate product development. As a joint subsidiary of two strong software project houses with over 1,000 experts, Twip supports companies in the areas of software development, IT consulting and growth strategies. Twip's mission is to shape a better future together with innovative start-ups.

www.twip.de

Note for the editors:

We are happy to arrange interviews or background discussions for you with Vantis co-founder and CEO Till Jansen

Press contact:

Annika Fähnle
E-Mail: [email protected]
Phone: 0157 92357123

Sources:
[1] https://www.bosch-stiftung.de/de/presse/2021/05/2035-fehlen-deutschland-rund-11000-hausaerzte-experten-empfehlen-den-aufbau-von

Record changed: 2025-04-10

Picture Swiss Biotech Association Global Village 2025 SBD25 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)